SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Jesse Owens

PatientJesse Owens
Date of birth1960-09-12
IdentifiersMRN HR-ML042-SYN; SSN (made up) 000-42-8319
Document date2026-06-24
AuthorClarence Whitfield-Arroyo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Day 1 of cycle 2 of nivolumab with carboplatin and pemetrexed. [S]

History of Present Illness

Mr. Owens comes before his second cycle, three weeks after the first. He has not smoked since the morning of cycle 1. Varenicline gave him mild nausea for the first week, which settled by taking it after food; his dreams are vivid but not upsetting. After cycle 1 he was tired for four days and mildly nauseated for two, needing ondansetron twice. He has had no diarrhea, rash, cough beyond his usual, breathlessness, headache, or yellowing. He has been to five pulmonary rehabilitation sessions and walks most mornings. The hepatitis and HIV tests before cycle 1 were negative. He has had no thoughts of self-harm. [S]

ElementDetail
Since the last visitCycle 1 three weeks ago; pulmonary rehabilitation started
TobaccoAbstinent for three weeks on varenicline
Side effectsFatigue for four days and mild nausea for two after cycle 1; no immune-related symptoms

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired for four days after cycle 1; weight 75.8 kg; no fever
GastrointestinalPositiveMild nausea for two days after cycle 1 and in the first week of varenicline; no diarrhea
RespiratoryNegativeMorning cough less since stopping smoking; no breathlessness
IntegumentaryNegativeNo rash or itching
EndocrineNegativeNo heat or cold intolerance or unusual thirst
NeurologicalNegativeNo numbness or tingling; no headache
PsychiatricNegativeMood good; vivid dreams on varenicline; PHQ-2 0

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 80.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7Oral route2026-05-26 to 2026-06-01completedS
Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse1 mg twice daily after foodOral route2026-06-02activeS
Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial)Day 1 every 21 days for three cyclesIntravenous route2026-06-03 to 2026-07-15completedS
Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cyclesDay 1 every 21 days for three cyclesIntravenous route2026-06-03 to 2026-07-15completedS
Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cyclesDay 1 every 21 days for three cyclesIntravenous route2026-06-03 to 2026-07-15completedS
Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the lastOne tablet dailyOral route2026-05-26 to 2026-08-05completedS
Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed)1000 mcg once; a second dose was not due before pemetrexed endedIntramuscular route2026-05-26 to 2026-05-26completedS
Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose4 mg twice daily for three days around each cycleOral route2026-06-02 to 2026-07-16completedS
Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy8 mg every 8 hours as neededOral route2026-06-03 to 2026-07-31completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-24Body height178cmS
2026-06-24Body weight75.8kgS
2026-06-24Body mass index (BMI) [Ratio]23.9kg/m2S
2026-06-24Systolic blood pressure126mm[Hg]S
2026-06-24Diastolic blood pressure78mm[Hg]S
2026-06-24Heart rate74/minS
2026-06-24Respiratory rate16/minS
2026-06-24Body temperature36.6CelS
2026-06-24Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-24Hemoglobin [Mass/volume] in Blood13.6g/dL13.5-17.5 g/dLNormalS
2026-06-24Leukocytes [#/volume] in Blood by Automated count6.910*3/uL4-11 10*3/uLNormalS
2026-06-24Neutrophils [#/volume] in Blood by Automated count4.110*3/uL1.5-7.7 10*3/uLNormalS
2026-06-24Platelets [#/volume] in Blood by Automated count21410*3/uL150-400 10*3/uLNormalS
2026-06-24Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.7-1.3 mg/dLNormalS
2026-06-24Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M84mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-06-24Glucose [Mass/volume] in Serum or Plasma101mg/dL70-99 mg/dLHighS
2026-06-24Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-55 U/LNormalS
2026-06-24Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma25U/L8-48 U/LNormalS
2026-06-24Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-06-24Thyrotropin [Units/volume] in Serum or Plasma2.6m[IU]/L0.4-4 mIU/LNormalS
2026-06-24Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.1ng/dL0.8-1.8 ng/dLNormalS
2026-06-24Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 2026-06-24; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 75.8 kg; blood pressure 126/78, pulse 74; oxygen saturation 96 percent
MouthNo ulcers
RespiratoryClear; no crackles
SkinNo rash
NeurologicalLight touch and vibration normal in the feet

Problems

ProblemClinical statusVerificationCodeProvenance
Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review bookedresolvedconfirmed R91.1S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit.
Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alterationactiveconfirmed C34.12S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable.
Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicineactiveconfirmed F17.210S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count with neutrophils and plateletsBefore each chemotherapy cycleCompleted todayHemoglobin 13.6, white cells 6.9, neutrophils 4.1, platelets 214
LaboratoryImmune-related adverse event laboratory panel: TSH, free T4, liver tests, creatinine and glucoseBefore each immunotherapy infusionCompleted todayTSH 2.6, free T4 1.1; ALT 28, AST 25, bilirubin 0.5; creatinine 1.0, eGFR 84; glucose 101 non-fasting the morning after dexamethasone
LaboratoryMorning cortisolBaseline and before each immunotherapy infusion (CMID); for symptomsDeferredMissed: the CMID schedule calls for cortisol before each infusion, but the cycle 2 order set did not include it and it was not drawn. No harm is expected: he has no fatigue beyond the days after chemotherapy, no low blood pressure, low sodium or dizziness. Corrective action: cortisol added to the standing order set for cycle 3 and to the blood tests before surgery
ExaminationImmune-related adverse event symptom review (diarrhea, rash, cough, breathlessness, headache, jaundice)Every visit on immunotherapyCompleted todayNone
ExaminationPeripheral neuropathy after platinumEvery visit during and after platinum therapyCompleted todayNo symptoms; light touch and vibration normal
Self-managementTobacco use and cessation treatmentEvery visitCompleted todayAbstinent three weeks on varenicline
SurveyDistress and depression screeningEvery visit; PHQ-9 and GAD-7 at diagnosis and at treatment transitionsCompleted todayPHQ-2 0
ExaminationDyspnea and cough assessmentEvery visitCompleted todayMorning cough lighter since stopping smoking; no breathlessness
Self-managementPulmonary rehabilitation (prehabilitation)Before and after lung resectionCompleted todayFive sessions attended
ImagingResponse imagingAfter the three cycles before surgeryDueRestaging CT after cycle 3

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021)

Follow-up: Cycle 3 in three weeks. Thoracic surgery review next week. Visit with restaging CT after cycle 3. Call the oncology line for any warning sign. Next scheduled visit 2026-08-05: after three cycles: restaging CT, decision for lobectomy, thyroid result and surgical preparation. [S]